Pharmacokinetics of CVL-231 Following Single Oral Administration of Modified- and Immediate-release Formulations in Fasted and Fed Healthy Participants
Study Details
Study Description
Brief Summary
A 2-part, crossover design, open-label treatment trial with 4 periods, 4 sequences (Part A) to evaluate MR formulations of CVL-231 and a 2 periods, 2 sequences (Part B) to understand effect of food on CVL-231 exposures from an MR formulation.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1 |
Detailed Description
CVL-231 is a muscarinic acetylcholine receptor (mAChR) activator that selectively binds to the M4 muscarinic receptor subtype (M4 mAChR) and is being developed for treatment of psychosis in schizophrenia. Part A of this 2-part trial will investigate the PK of CVL-231 in healthy participants following a single oral dose of CVL-231 as 3 modified-release (MR) formulations with different release rates and an immediate-release (IR) formulation under fasted conditions. Upon selection of an MR formulation with appropriate PK characteristics, the effect of food on the PK of CVL-231 and its metabolite following single oral doses of the selected MR formulation may be evaluated in Part B.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Part A: Single doses of CVL-231 IR/MR formulations in healthy participants under fasted conditions Oral Dose |
Drug: 10 mg CVL-231 as IR formulation
Tablets
Drug: 30 mg CVL-231 as slow-release MR formulation
Capsules
Drug: 30 mg CVL-231 as medium release MR formulation
Capsules
Drug: 30 mg CVL-231 as fast release MR formulation
Capsules
|
| Experimental: Part B: Single doses of CVL-231 target release formulation under fasted and fed conditions Oral Dose |
Drug: 30 mg CVL-231 Target Release, Fasted
Capsules
Drug: 30 mg CVL-231 Target Release, Fed
Capsules
|
Outcome Measures
Primary Outcome Measures
- Primary Part A & B: Peak Plasma Concentration (Cmax) for CVL-231 and Metabolite (CV-0000364) [Up to 72 Hours in each period]
- Primary Part A & B: Time to Maximum Concentration (Tmax) for CVL-231 and Metabolite (CV-0000364) [Up to 72 Hours in each period]
- Primary Part A & B: Time prior to the first measurable (non-zero) concentration (Tlag) for CVL-231 and Metabolite (CV-0000364) [Up to 72 Hours in each period]
- Primary Part A & B: Area under the plasma concentration-time curve from time 0 to the last measurable time point (AUClast) for CVL-231 and Metabolite (CV-0000364) [Up to 72 Hours in each period]
- Primary Part A & B: Area under the plasma concentration-time curve from time zero to infinity (AUCinf) for CVL-231 and Metabolite (CV-0000364) [Up to 72 Hours in each period]
- Primary Part A & B: Elimination half-life (t½) for CVL-231 and Metabolite (CV-0000364) [Up to 72 Hours in each period]
- Primary Part A only: Dose normalized Cmax, derived by Cmax divided by the dose administered (Cmax/D) for CVL-231 and Metabolite (CV-0000364) [Up to 72 Hours in each period]
- Primary Part A only: Dose normalized AUClast, derived by AUClast divided by the dose administered (AUClast/D) for CVL-231 and Metabolite (CV-0000364) [Up to 72 Hours in each period]
- Primary Part A only: Dose normalized AUCinf, derived by AUCinf divided by the dose administered (AUCinf/D) for CVL-231 and Metabolite (CV-0000364) [Up to 72 Hours in each period]
Secondary Outcome Measures
- Secondary: Incidence and Severity of Treatment Emergent Adverse Events (TEAEs) [Up to Day 14]
- Secondary: Incidence of clinically significant changes in electrocardiogram (ECG) results [Up to 72 Hours in each period]
Assessment of clinically significant changes in QT intervals measured by 12-lead ECG recording after the participant has been supine and at rest for at least 3 minutes.
- Secondary: Incidence of clinically significant changes in clinical laboratory results [Up to 72 Hours in each period]
- Secondary: Incidence of clinically significant changes in vital sign measurements [Up to 72 Hours in each period]
Assessment of clinically significant changes in vital signs including temperature, systolic and diastolic blood pressure, and heart rate.
- Secondary: Incidence of clinically significant changes in physical and neurological examination results [Up to 72 Hours in each period]
- Secondary: Clinically significant findings in suicidality assessed using the Columbia Suicide-Severity Rating Scale (C-SSRS) [Up to 72 Hours in each period]
The C-SSRS rates an individual's degree of suicidal ideation (SI) on a scale, ranging from "wish to be dead" to "active suicidal ideation with specific plan and intent." The scale identifies SI severity and intensity, which may be indicative of an individual's intent to commit suicide. C-SSRS SI severity subscale ranges from 0 (no SI) to 5 (active SI with plan and intent).
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Women of nonchildbearing potential and men 18 to 55 years, inclusive.
-
Healthy as determined by medical evaluation, including medical and psychiatric history, physical and neurological examinations, ECG, vital sign measurements, and laboratory test results, as evaluated by the investigator.
-
Body mass index of 18.5 to 30.0 kg/m2 and a total body weight >50 kg (110 lbs).
-
Sexually active men with a pregnant or a nonpregnant partner of childbearing potential must agree to comply with protocol contraception requirements during treatment and through 7 days post dose. In addition, male participants should not donate sperm for a minimum of 7 days following the last dose of IMP.
-
Capable of giving signed informed consent.
-
Ability, in the opinion of the investigator, to understand the nature of the trial and comply with protocol requirements.
Exclusion Criteria:
-
Current history of significant cardiovascular, pulmonary, gastrointestinal, renal, hepatic, metabolic, endocrine, hematological, immunological, or neurological disease that, in the opinion of the investigator or medical monitor, could compromise either participant safety or the results of the trial.
-
Current or past personal or family history of any psychiatric disorder as classified by DSM-5 criteria.
-
Epilepsy or a history of seizures except for a single seizure episode, eg, a childhood febrile seizure, a seizure related to trauma or alcohol withdrawal, or an unexplained loss of consciousness.
-
History of moderate to severe substance or alcohol-use disorder (excluding caffeine) within 12 months prior to signing the ICF.
-
Serious risk of suicide in the opinion of the investigator
-
Receipt of SARS-CoV2 vaccine or booster within 28 days of dosing with CVL-231, or plan to receive SARS-CoV2 vaccination or booster from Screening through 5 days after last dose of CVL-231.
-
Have recently been diagnosed with symptomatic COVID-19 or test positive for COVID-19 within 30 days prior to signing the ICF.
-
Either of the following:
-
History of HIV, hepatitis B, or hepatitis C infection
-
Positive result for HIV antibody, hepatitis B surface antigen, hepatitis B core antibody, or hepatitis C antibody
-
Positive drug screen for illicit drugs or a positive test for alcohol
-
12-lead ECG demonstrating pre-defined abnormalities at Screening and Day -1 based on local evaluation.
-
Abnormal clinical laboratory tests or vital sign measurements at the Screening Visit and at Day -1 (check-in) for each period
-
Known to be allergic or hypersensitive to the IMP or any of its components.
-
Participation in any clinical trial within 90 days prior to signing the ICF.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Celerion Inc. | Tempe | Arizona | United States | 85283 |
Sponsors and Collaborators
- Cerevel Therapeutics, LLC
Investigators
- Study Director: Matthew Leoni, MD, MBA, Cerevel Therapeutics, LLC
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- CVL-231-1004